Understanding the Connection Between Isotretinoin and Dry Eye
Isotretinoin is a powerful oral medication prescribed for severe acne that does not respond to other treatments. It works by shrinking the sebaceous glands, which are small oil-producing glands found throughout the skin. By reducing the size and activity of these glands, isotretinoin dramatically lowers the amount of oil the skin produces, which helps clear persistent acne breakouts.
While isotretinoin can be very effective for treating stubborn acne, it affects oil glands throughout the entire body. This means it does not only target the skin on the face or back. It also impacts other oil-producing glands, including specialized glands located in the eyelids. This widespread effect is what creates a direct connection between isotretinoin use and dry eye disease.
Your tear film is a thin, complex layer of fluid that coats the front surface of your eye every time you blink. It is made up of three main layers that work together to keep your eyes comfortable and healthy. The outermost layer is a thin oil (lipid) layer that prevents your tears from evaporating too quickly. Beneath that is a thick watery (aqueous) layer that provides moisture, nourishment, and protection. The innermost layer is a mucus layer that helps the tears spread evenly and stick to the eye's surface.
When all three layers are balanced, your tear film stays stable between blinks. This stability protects the delicate surface of your eye from friction, dryness, and irritation. When any one of these layers is disrupted, the tear film breaks down faster than it should, leading to dry eye symptoms.
The oil layer of the tear film is produced by tiny glands called meibomian glands (specialized oil glands embedded along the edges of your upper and lower eyelids). Because isotretinoin is designed to shrink sebaceous glands, it also shrinks and damages the meibomian glands. Clinical studies reviewed in the TFOS DEWS III report on medication-induced dry eye confirm that isotretinoin causes meibomian gland atrophy, meaning the glands physically shrink and lose their ability to function properly.
When the meibomian glands are damaged, they produce less oil and the oil they do produce is often of lower quality. Without a healthy oil layer on top of your tears, the watery layer underneath evaporates much faster than normal. This type of dry eye is called evaporative dry eye, and it is the primary form of dry eye disease linked to isotretinoin use.
Research indicates that a significant number of patients on isotretinoin develop evaporative dry eye symptoms within the first few months of treatment. Doctors measure tear film health using a test called tear breakup time (TBUT), which tracks how many seconds your tear film remains stable after a blink. In patients taking isotretinoin, TBUT drops significantly, meaning the tear film falls apart much sooner than it should.
Patients frequently notice symptoms such as a gritty or sandy feeling in the eyes, burning or stinging, redness, blurred vision that comes and goes, and increased sensitivity to light. These symptoms can develop gradually and may worsen over the course of isotretinoin treatment.
Beyond simply reducing oil production, isotretinoin often causes noticeable eyelid inflammation. The edges of the eyelids may become red, swollen, or crusty. This condition is closely related to meibomian gland dysfunction (a condition where the oil glands in the eyelids are blocked or not working correctly). Eyelid inflammation makes dry eye symptoms worse because it further disrupts the quality and flow of the oil layer, creating a cycle of irritation and tear film instability.
One of the most important things to understand is that while dry eye symptoms often improve after stopping isotretinoin, the structural damage to the meibomian glands can sometimes be long-lasting. In some cases, the glands do not fully recover their original size or function even after the medication is discontinued. This means some patients may experience ongoing dry eye symptoms that require continued management well after their acne treatment has ended.
The degree of gland damage varies from person to person. Factors such as the dosage of isotretinoin, the length of treatment, and individual differences in gland resilience all play a role. Early detection and proactive care can help protect the glands and reduce the risk of lasting damage.
Who Is Most at Risk for Isotretinoin-Related Dry Eye
The risk of developing dry eye increases with both the dosage and the duration of isotretinoin treatment. Patients who take higher daily doses or who remain on the medication for extended periods are more likely to experience significant meibomian gland changes. If you are starting a course of isotretinoin, it is worth having a conversation with both your dermatologist and your eye care provider about monitoring your eye health throughout treatment.
If you already experience mild dry eye symptoms or have a history of eyelid inflammation before starting isotretinoin, you may be at greater risk for more severe symptoms during treatment. Pre-existing meibomian gland dysfunction means the glands are already compromised, and the added stress of isotretinoin can push them further toward significant dysfunction.
Wearing contact lenses requires a stable, well-lubricated tear film. Patients who wear contact lenses and take isotretinoin may find that their lenses become increasingly uncomfortable as the oil layer of the tear film deteriorates. In some cases, patients may need to temporarily switch to glasses during their isotretinoin treatment to reduce eye surface irritation.
Isotretinoin is most commonly prescribed to teenagers and young adults. This age group may not be aware of the signs of dry eye disease or may not connect their eye discomfort to their acne medication. It is important for younger patients and their families to understand that eye dryness, irritation, or visual changes during isotretinoin treatment are not normal and should be reported to an eye care professional promptly.
Environmental factors can compound the effects of isotretinoin on the tear film. If you live in a dry climate, spend a lot of time in air-conditioned or heated spaces, or are frequently exposed to wind, your tears evaporate even faster. These environmental stressors combined with a weakened oil layer from isotretinoin can make dry eye symptoms significantly worse.
Extended screen use reduces your blink rate, which means your tear film is refreshed less often. When the oil layer is already compromised by isotretinoin, a lower blink rate accelerates tear evaporation. Patients taking isotretinoin who spend many hours on computers, phones, or tablets may notice their dry eye symptoms are more pronounced during and after screen time.
What to Expect When Managing Isotretinoin-Related Dry Eye
The TFOS DEWS III management guidelines recommend a proactive approach for patients beginning isotretinoin. Rather than waiting for dry eye symptoms to appear, it is best to start protective eye care at the same time as the medication. This typically includes using preservative-free artificial tears that contain a lipid (oil) component. These specialized drops help supplement the oil layer that the meibomian glands can no longer produce effectively.
Daily warm compress therapy is also recommended from the start. Warm compresses involve placing a clean, warm cloth or a specially designed heated eye mask over the closed eyelids for several minutes. The gentle heat helps soften any thickened oil in the meibomian glands and encourages healthier oil flow onto the tear film.
Regular eye exams during isotretinoin treatment are important for catching changes early. Your eye care provider can measure your tear breakup time, evaluate the health of your meibomian glands, and check for signs of eyelid inflammation. These measurements provide a baseline and allow your care team to adjust your dry eye management plan if your symptoms change.
At Washington Eye Institute, our multidisciplinary ophthalmology and optometry team provides comprehensive eye exams that include detailed assessments of the tear film and meibomian gland function. This thorough approach helps identify problems early, before they lead to significant discomfort or lasting gland damage.
Many patients find that their dry eye symptoms begin to improve within weeks to months after completing their isotretinoin course. However, because structural gland damage can persist, some patients continue to experience symptoms that require management. Your eye care provider will work with you to create a long-term care plan based on the current health of your meibomian glands and the severity of your symptoms.
If preservative-free tears and warm compresses are not providing enough relief, your eye care provider may recommend additional treatments. Intense Pulsed Light (IPL) therapy is a gentle, light-based treatment that targets inflammation along the eyelids and helps restore healthier meibomian gland function. IPL works by reducing the inflammation and bacterial buildup around the glands, allowing them to produce better quality oil over time.
Punctal plugs are another option for patients who need additional moisture. These are tiny, painless devices placed in the small drainage openings (puncta) of the eyelids. By slowing the drainage of tears from the eye's surface, punctal plugs help your natural tears stay on the eye longer, providing more consistent lubrication and comfort.
Managing isotretinoin-related dry eye works best when your dermatologist and eye care team communicate. Your dermatologist manages your acne treatment plan, while your eye care provider monitors and treats the ocular side effects. At Washington Eye Institute, our team is experienced in coordinating care with dermatologists to help ensure your eyes are protected throughout your acne treatment journey.
Whether your dry eye symptoms resolve after stopping isotretinoin or continue to require management, building good eye care habits benefits your long-term comfort. Staying hydrated, using a humidifier in dry indoor environments, taking regular breaks during screen time (following the 20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds), and continuing to use preservative-free tears as needed are all simple steps that support a healthy tear film.
Frequently Asked Questions
Not everyone who takes isotretinoin will develop significant dry eye symptoms. However, research shows that a large portion of patients do experience some degree of tear film disruption during treatment. The severity varies based on factors like dosage, treatment length, and individual gland health. Starting protective eye care early can help reduce your risk and the severity of any symptoms that do develop.
You should not stop or change your isotretinoin dosage without first consulting the physician who prescribed it. Dry eye symptoms during isotretinoin treatment can often be managed with supportive care, including preservative-free artificial tears and warm compresses. If your symptoms are severe, your prescribing physician and eye care provider can work together to find the best path forward for both your skin and your eyes.
For many patients, dry eye symptoms begin to improve within a few weeks to months after stopping the medication. However, if the meibomian glands have experienced significant structural changes, some degree of dry eye may persist longer. Regular follow-up with your eye care provider can help determine whether additional treatment is needed to support your recovery.
Contact lens comfort often decreases during isotretinoin treatment due to the reduced oil layer on the tear film. Some patients can continue wearing contacts with the help of preservative-free rewetting drops and shorter daily wear times. Others may find it more comfortable to switch to glasses temporarily. Your eye care provider can help you decide what works best for your situation.
Evaporative dry eye happens when the oil layer of the tear film is insufficient, causing tears to evaporate too quickly. This is the type most commonly associated with isotretinoin use. Aqueous-deficient dry eye occurs when the lacrimal glands (the glands that produce the watery layer of tears) do not make enough fluid. Some patients experience a combination of both types. A comprehensive eye exam can determine which type is affecting you and guide the most effective treatment approach.
Yes. Starting warm compress therapy and lipid-containing, preservative-free artificial tears before or at the very beginning of isotretinoin treatment can help support meibomian gland health. Regular eye exams during treatment allow your provider to monitor the glands closely and recommend additional therapies if changes are detected early. Taking these proactive steps may help reduce the risk of long-lasting gland damage.